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Bariatric surgery (BS) results in sustained weight loss and may reverse inflammation,
metabolic alterations, extracellular matrix remodeling and arterial stiffness. We
hypothesize that increased stiffening in omental arteries from obese patients might be
associated with an increase in MMP activity and a decrease in p-AMPK, together with
systemic oxidative stress and inflammation. Moreover, BS could contribute to reversing
these alterations. This study was conducted with 38 patients of Caucasian origin:
31 adult patients with morbid obesity (9 men and 22 women; mean age 46 years and
BMI = 42.7 ± 1.0 kg/m2) and 7 non-obese subjects (7 women; mean age 45 years
and BMI = 22.7 ± 0.6 kg/m2). Seventeen obese patients were studied before and
12 months after BS. The stiffness index β, an index of intrinsic arterial stiffness, was
determined in omental arteries and was significantly higher in obese patients. Levels of
phosphorylated AMPK (p-AMPKThr−172) and SIRT-1 were significantly lower in peripheral
blood mononuclear cells (PBMCs) from obese patients than those from non-obese
patients (p < 0.05) and were normalized after BS. Total and active MMP-9 activities,
LDH, protein carbonyls and uric acid were higher in obese patients and reduced by
BS. Moreover, there was a correlation between plasmatic LDH levels and the stiffness
index β. BS has a beneficial effect on abnormal MMP-9, LDH and AMPK activities that
might be associated with the development of arterial stiffness in obese patients. Since
these parameters are easily measured in blood samples, they could constitute potential
biomarkers of cardiovascular risk in morbid obesity.
Keywords: obesity, bariatric surgery, matrix metalloproteinase-9, AMP-activated protein kinase, lactate
dehydrogenase, intrinsic arterial stiffness
Abbreviations: AMPK, AMP-dependent protein kinase; BMI, body mass index; BS, bariatric surgery; BW, body weight;
CRP, C reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; ECM, extracellular matrix; HOMA-IR,
insulin resistance index; LDH, lactate dehydrogenase; MMP, matrix metalloproteinases; ROS, reactive oxygen species; SBP,
systolic blood pressure; SIRT, sirtuin; UA, uric acid; VSMCs, vascular smooth muscle cells; WC, waist circumference.
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INTRODUCTION
Obesity constitutes a major social problem worldwide and
is associated with insulin resistance, diabetes, and a higher
risk of cardiovascular disease (CVD) (Morris, 2008). The
increased accumulation of adipose tissue, especially in a visceral
location, is strongly associated with a systemic pro-inflammatory
and pro-oxidative state, leading to endothelial dysfunction,
vascular remodeling, and arterial stiffness (Sutton-Tyrrell et al.,
2001; Brunner et al., 2015; Morigami et al., 2016). Systemic
arterial stiffness, assessed by pulse wave velocity (PWV) or the
augmentation index is a classic feature of vascular aging and an
independent predictor of cardiovascular morbidity and mortality
(Turin et al., 2010; Vlachopoulos et al., 2010). Body fat and central
adiposity have been suggested as predictors of accelerated arterial
stiffness that develops at younger ages in obese patients (Nemes
et al., 2008; Grassi and Diez, 2009; Kangas et al., 2013; Brunner
et al., 2015; Satoh-Asahara et al., 2015). Stiffness index β, obtained
from the stress–strain relationship (Dobrin, 1978), is currently a
well-accepted marker of intrinsic arterial stiffness and it has been
determined in several studies performed in human resistance
arteries (Savoia et al., 2008; Fonck et al., 2009; Grassi et al., 2010).
In addition, the increase of intrinsic stiffness of large arteries is
now considered an independent predictor of cardiovascular (CV)
diseases (Bouissou et al., 2014) and precedes changes in systemic
arterial stiffness (Sehgel et al., 2013).
A variety of pathophysiological mechanisms might underlie
the arterial stiffness development associated with obesity. AMP-
activated protein kinase (AMPK) is a Ser/Thr protein kinase
that senses cell energy status and contributes to restoring energy
homeostasis (Hardie, 2007; Hue and Rider, 2007). AMPKα, the
catalytic subunit of AMPK that is activated via phosphorylation
(Dammanahalli and Sun, 2008; Chen et al., 2015), plays a
protective role in vascular function (Garcia-Prieto et al., 2015b,c)
and prevents the activation of mechanisms implicated in the
development of arterial stiffness (for review see Garcia-Prieto
et al., 2015a; Salt and Hardie, 2017). Dysregulation of AMPK
is a pathogenic factor for the development of vascular disease
(Lee et al., 2005) in genetic obese animal models (Ruderman
et al., 2013) and humans (Gauthier et al., 2011; Ruderman et al.,
2013). In severely obese patients before bariatric surgery (BS),
the downregulation in AMPK activity in adipose tissue is linked
to increased visceral adiposity, oxidative stress and inflammation
(Gauthier et al., 2011; Xu et al., 2012).
Sirtuins, SIRT1–SIRT7, comprise a family of NAD+-depen-
dent enzymes. The most studied is SIRT1, an NAD+-dependent
protein deacetylase that protects against CVD (for review see
Winnik et al., 2015). It has been shown to reduce arterial stiffness
and endothelial dysfunction by inhibiting inflammatory and
oxidant pathways (Gano et al., 2014; Fry et al., 2016). SIRT1
might be activated by caloric restriction and increased energy
expenditure (Cohen et al., 2004; Civitarese et al., 2007; Chen
et al., 2008), but downregulated by energy oversupply (Pfluger
et al., 2008). In fact, SIRT1 expression is significantly reduced in
adipose tissue from obese humans (Xu et al., 2013).
Matrix metalloproteinases (MMPs) are a large family of
endopeptidases that can proteolyze all components of the
extracellular matrix (ECM). MMP-2 and MMP-9 are involved
in the cleavage of denatured collagen (gelatin), elastin and type
IV collagen in blood vessels (Spinale, 2007) and in adipogenesis,
vascular remodeling, and inflammation (Jaiswal et al., 2011).
Therefore, MMP-9 seems to favor arterial stiffness and the
development and progression of hypertension (Flamant et al.,
2007; Zhou et al., 2007). In obese subjects, both MMP-2
and MMP-9 plasma levels are increased (Derosa et al., 2008;
Andrade et al., 2012).
Weight loss is associated with an improvement in cardio-
metabolic disorders (Sjostrom et al., 2012). Since BS constitutes
the most effective strategy for treating morbidly obese patients
(Fruhbeck, 2015), it is a useful approach to search for new
potential biomarkers of obesity-associated cardiovascular risk.
We hypothesize that obese patients show a decrease in p-AMPK
and an increase in MMPs activity associated with systemic
oxidative stress and inflammation, and that body weight
reduction derived from BS could significantly contribute to
reversing these alterations. Therefore, the aim of this study was
to evaluate the effect of BS on: (i) oxidative and inflammatory
markers, (ii) AMPK activity and SIRT-1 expression, (iii) MMP-
9 activity and LDH levels, and (iv) the stiffness index β.
Changes in these parameters might allow the definition of
potential biomarkers for the development of obesity-related
arterial stiffness.
MATERIALS AND METHODS
Study Population
As shown in Figure 1, this study was conducted with 38
subjects of Caucasian origin: 31 adult patients with morbid
obesity [9 men and 22 women; mean age 46 years (range
27–62 years) and BMI = 42.7 ± 1.0 kg/m2] and 7 non-obese
control subjects [7 women; mean age 45 years (range 33–55 years)
and BMI = 22.7 ± 0.6 kg/m2 without other comorbidities]. The
obese group was divided into two subgroups: (i) a group not
undergoing BS (non-surgery group, 14 patients) and (ii) a group
undergoing BS (pre-surgery group, 17 patients). The pre-surgery
group was studied before and 12 months after BS. All pre-surgery
patients underwent bariatric surgery [BS, elective laparoscopic
bypass (53%) or sleeve gastrectomy (47%)] in the same center.
The main inclusion criteria for BS was the presentation of more
severe comorbidities (poorly controlled diabetes, ischemic heart
disease, renal insufficiency or muscular neurological diseases)
than in the non-surgery group. Patients were submitted to BS
in chronologic order. Patients in the non-surgery group did not
undergo BS because they rejected it for personal reasons and
they preferred to receive counseling on lifestyle modifications
(hypocaloric diet and exercise). They did not receive any
pharmacological treatment for losing weight. Exclusion criteria
were any past or present history of benign or malignant tumor,
an inflammatory or autoimmune disorder and acute infections.
Blood samples were obtained before BS and at 12 months follow-
up. Information regarding anthropometric, clinical data and
laboratory parameters was collected and included: age, body
weight (BW), body mass index (BMI), waist circumference (WC),
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FIGURE 1 | Scheme explaining the study design and the patient selection process.
systolic (SBP), and diastolic blood pressure (DBP), complete
hemogram, lipid profile, fasting glucose, glycosylated hemoglobin
(HbA1c), insulin, homeostasis model assessment of insulin
resistance index (HOMA-IR), C-reactive protein (CRP), lactate
dehydrogenase (LDH), carbonyls, and uric acid (UA) levels.
Small samples of omental adipose tissue were obtained from
patients who underwent BS during the intervention. In addition,
detailed clinical information was collected, including the patients’
comorbidities and medication. This study was approved by
the Ethics Committee of the Hospital Clínico San Carlos and
Universidad San Pablo-CEU and was conducted in compliance
with the Helsinki Declaration. All patients signed a written
informed consent form before they were included in the study.
Blood Sample Collection
Blood samples from obese and non-obese subjects were collected
under fasting conditions in citrated-BD Vacutainer Plus plastic
serum tubes (Plymouth, United Kingdom). A total of 1 ml of
blood was centrifuged at 3000 rpm for 10 min at 4◦C to obtain
plasma. A total of 5 ml of blood were diluted with PBS (pH = 7.4)
(1:1 ratio) and submitted to a Ficoll-Hypaque (Sigma-Aldrich,
United States) density gradient. After centrifugation at 1800 rpm
for 30 min at 4◦C, the mononuclear cell interface was collected,
washed with PBS and centrifuged at 1200/1500 rpm for 5 min
at 4◦C. Both plasma and peripheral blood mononuclear cells
(PBMCs) were frozen at−80◦C until assay.
Western Blot Analysis
Protein expression was determined in PBMCs by Western
blot, as previously described (Somoza et al., 2007). Briefly,
20 µg protein samples were separated by SDS-PAGE gels.
Primary antibodies anti p-AMPKα (Thr172) and AMPKα
(1:1000 final dilution; Cell Signaling Biotechnology, Germany)
and SIRT-1 (D1D7) (1:1000 final dilution; Cell Signaling
Technology, United States) were applied overnight at 4◦C.
After washing, appropriate secondary antibodies (anti-rabbit
or anti-mouse IgG-peroxidase conjugated) were applied for
1 h (1:5000 final dilution). Blots were washed, incubated
in commercial enhanced chemiluminescence reagents (ECL
Prime, Amersham Bioscience, United Kingdom) and bands were
analyzed with the ChemiDoc XRS+ Imaging System (Bio-Rad,
United States). To prove equal loading of samples, blots were
incubated with β-actin antibody (1:5000 final dilution; Sigma-
Aldrich, United States). Blots were quantified using Image
Lab 3.0 software (Bio-Rad, United States). Expression values
of p-AMPKα and SIRT-1 were normalized with AMPKα and
β-actin, respectively.
MMP-2 and MMP-9 Activity in Plasma
MMP-2 and MMP-9 gelatinase activity was determined by
gelatin zymography. Total protein concentration was measured
with the Bradford method (Bradford, 1976). Human plasma
samples were diluted 1:1 with sample buffer and subjected to
SDS-polyacrylamide gel electrophoresis (PAGE) containing
0.1% gelatin. Subsequently, gels were renatured and incubated
for 12 h at 37◦C. Gels were stained with Coomassie blue (Bio-
Rad, United States) and, after destaining, gelatinolytic activity
of MMP-2 and MMP-9 was detected as transparent bands
against the background of the blue-stained gels. Transparent
bands are the result of the digestion of gelatin, the substrate
incorporated in polyacrylamide gel, because of enzymatic
activity of MMP-2 and MMP-9. Bands were quantified using
Image Lab 3.0 software (Bio-Rad, United States). The active
MMP-9 form was determined using a commercial kit and
following the manufacturer’s specifications (QuickZyme
Biosciences, Netherlands).
Plasma Carbonyls Analysis
Circulating carbonyl levels, as an index of oxidative marker
on proteins, were assessed in plasma samples using the 2,
4-dinitrophenylhydrazine (DNPH)-based assay adapted to a
microplate reader (Hawkins et al., 2009; Ruiz-Hurtado et al.,
2014). Total protein carbonyls concentration was measured using
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the extinction coefficient of DNPH (ε = 22,000/mol/cm) and
expressed as nmol/mg protein.
Study of Vascular Mechanical Properties
Omental arteries were dissected from samples of omental adipose
tissue from patients undergoing BS and were carefully cleaned
of their surrounding adipose tissue. Mechanical properties
were analyzed with a pressure myograph (Model P100, Danish
Myo-Tech), as previously described (Briones et al., 2003; Gil-
Ortega et al., 2016). Briefly, intraluminal pressure was set for
equilibration at 70 mmHg for 30 min at 37◦C in calcium-
free KH (0Ca2+; omitting calcium and adding 10 mM EGTA)
and bubbled with carbogen (95% O2/5% CO2). Afterwards,
intraluminal pressure was augmented at 20 mmHg intervals
(5, 20, 40, 60, 80, 100, 120, and 140 mmHg) and both external
and internal diameters (Di0Ca, De0Ca) were recorded and analyzed
with Myoview software. From the De0Ca and Di0Ca values, we
calculated: (i) the circumferential wall strain (ε) = (Di0Ca −
D00Ca)/D00Ca, where D00Ca is the diameter at 3 mmHg and
Di0Ca is the observed internal diameter for a given intravascular
pressure in 0Ca2+ KH and (ii) the circumferential wall stress
(β = (P × Di0Ca)/(2WT)), where P is the intraluminal pressure
(1 mmHg = 1.334 dynes cm−2) (Briones et al., 2003). The
stiffness index β, obtained from the stress-strain relationship, is
proportional to Young’s incremental elastic modulus and is used
to assess the intrinsic arterial stiffness independently of vessel
geometry (Dobrin, 1978).
Statistical Analysis
Continuous variables were compared using the Student’s t-test
or one-way analysis of variance (ANOVA) following Newman–
Keuls test. Data are reported as mean ± SEM. Correlation
analyses were performed through linear regression and analyzed
by Pearson’s correlation. All statistical analyses were performed
using Graph-Pad Prism 7.0 or Origin 9.0 software. Statistical
significance was set at P < 0.05.
RESULTS
Clinical Characteristics
Anthropometric and clinical parameters at baseline and at 12
months follow-up are summarized in Table 1. At baseline,
the obese group, especially the pre-surgery group, exhibited a
higher number of CV risk factors than non-obese subjects, who
did not present any comorbidity. In the pre-surgery group,
14 (82.4%) patients were diagnosed with type 2 diabetes mellitus
(T2DM, 76.5% treated with metformin therapy), 10 (58.8%)
with hypertension (all treated with either an ACEi or ARB)
and 11 (64.7%) with dyslipidemia (all treated with statins).
In the non-surgery group, no patient was diagnosed with
T2DM, 8 (57.1%) patients were diagnosed with hypertension (all
treated with ACEi or ARB) and 9 (64.3%) with dyslipidemia
(all treated with statins).
Anthropometric parameters including BW, BMI and WC
were significantly higher in obese patients than in controls
(P < 0.001, Table 1) and significantly reduced 12 months after
BS (% of reduction: BW = 29.7%; BMI = 31.6%; and WC = 28.5%
in female and 25.8% in male) compared with their corresponding
pre-surgery values (P < 0.001 in all cases). BS significantly
reduced fasting glucose level and improved insulin sensitivity
(HOMA-IR) (P < 0.001). Lower HDL-cholesterol and higher
triglyceride (TG) levels were detected in obese patients than in
the control group. However, although these parameters were
not significantly modified by BS, a reduction in TG levels was
observed (P = 0.068 vs. obese). SBP and DBP were similar
between groups, which shows proper blood pressure control
in obese patients treated with ACEi/ARBs. In addition, as
shown in Table 1, the intake of antihypertensive drugs was
reduced after BS.
Since no differences were detected between non-surgery
and pre-surgery groups in carbonyls, UA, LDH, inflammatory
markers, AMPK and MMP-9 activities and SIRT-1 levels (data
not shown), these parameters were analyzed altogether, and we
will refer to them as the obese group.
Bariatric Surgery Significantly Reduces
Protein Oxidative Damage and
Inflammatory Markers/Cells
in Obese Patients
Levels of plasma carbonyls (Figure 2A; P < 0.001) and UA
(Figure 2B; P < 0.05), were significantly higher in obese
patients than in controls. After BS, carbonyls and UA levels
were significantly reduced (P < 0.05 vs. obese) and correlated
positively with BMI (r = 0.633 and P < 0.001; Figure 2C and
r = 0.408 and P < 0.01; Figure 2D, respectively).
As shown in Table 2, CRP was over sixfold higher in
obese patients than in the non-obese group (P < 0.01), but
significantly reduced after BS (P < 0.05). We also quantified
in blood samples the cell number of neutrophils, eosinophils,
monocytes and lymphocytes. Immune cell number was similar
in obese and control subjects. Post-surgery patients exhibited
a significant reduction in the amount of these immune cells,
except for eosinophils (P < 0.05 vs. obese; Table 2). Simple
regression analysis revealed a positive correlation between total
leukocytes, lymphocytes, neutrophils, monocytes or eosinophils
and BMI (Figure 3).
Bariatric Surgery Improves Both AMPK
Activity and SIRT-1 Expression in PBMCs
From Obese Patients
p-AMPKαThr172 levels (Figure 4A) were significantly lower
in PBMCs from obese patients than in those from the
control group (P < 0.01) but were restored to normal
values 12 months after surgery (P < 0.001 vs. obese levels).
The negative correlation between p-AMPKαThr172 and BMI
(Figure 4B; r = 0.655, P < 0.001) evidences greater AMPK
activity in post-surgery patients with a lower BMI than in
obese patients with a higher BMI. A negative correlation
was observed between p-AMPKαThr172 and plasma carbonyls
(r =−0.709 and P < 0.001).
SIRT-1 expression was significantly lower in obese patients
(P < 0.05 compared with controls) but reached normal values
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TABLE 1 | Patients’ characteristics.
Variable Non-obese control Obese Obese post-surgery
(N = 7) (N = 31) (N = 17)
No surgery Pre-surgery
(N = 14) (N = 17)
Sex-N (%) female 7 (100%) 11 (78.6%) 11 (64.7%) —
Age (years) 45.0 ± 4.5 41 ± 2.7 48.6 ± 2.5 —
Weight (Kg) 58.3 ± 3.3$ 121.0 ± 6.3### 113.7 ± 4.0### 79.9 ± 4.0∗∗∗
BMI (kg/m2) 22.7 ± 0.6$$ 43.7 ± 1.9### 41.8 ± 0.9### 28.6 ± 1.1∗∗∗
WC (cm)
Men — 150.0 ± 5.8 136.1 ± 5.6 101.0 ± 6.0∗∗
Women 83.6 ± 1.8 111.4 ± 4.6### 118.0 ± 3.2### 84.4 ± 2.9∗∗∗
Hypertension-N (%) — 8 (57.1%) 10 (58.8%) 6 (35.3%)
SBP (mmHg) 127.7 ± 8.4 121.5 ± 2.4 129.8 ± 4.3 134.8 ± 4.6
DBP (mmHg) 83.4 ± 2.3 77.7 ± 2.2 77.9 ± 2.4 79.7 ± 3.3
ACEi/ARBs user — 8 (57.1%) 10 (58.8%) 6 (35.3%)
Dyslipidemia-N (%) — 9 (64.3 %) 11 (64.7 %) 5 (29.4 %)
LDL-cholesterol (mg/dL) 119.1 ± 6.1 116.3 ± 6.9 120.9 ± 18.9 101.2 ± 8.9
HDL-cholesterol (mg/dL) 61.9 ± 2.5 48.4 ± 2.5# 48.3 ± 3.5# 48.4 ± 3.1#
Total cholesterol (mg/dL) 194.3 ± 9.0 210.2 ± 15.7 185.0 ± 10.1 172.9 ± 11.6
Triglycerides (mg/dL) 65.6 ± 5.4$ 142.1 ± 22.1# 171.2 ± 22.0## 126.6 ± 13.4
Statins user — 9 (64.3%) 11 (64.7%) 5 (29.4%)
T2DM-N (%) — — 14 (82.4%) 8 (47.0%)
Glucose (mg/dL) 88.7 ± 2.0 104.4 ± 4.3 162.6 ± 15.7###,& 102.8 ± 6.5+++
HbA1c (mmol/mol) — 38.0 ± 1.3 55.3 ± 4.4&& 41.9 ± 2.4++
Insulin (µIU/ml) 8.8 ± 0.2 33.2 ± 7.6## 36.2 ± 5.9## 11.1 ± 2.01∗∗∗
HOMA-IR 1.7 ± 0.3 8.4 ± 1.8## 6.9 ± 1.3## 2.7 ± 0.6+++
Metformin user — — 13 (76.5%) 8 (47.1%)
Demographic, anthropometric, obesity-related comorbidities, and biochemical parameters. Data are expressed as mean ± SEM. Data were compared using one-way
ANOVA, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. obese; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. control; $P < 0.05, $$P < 0.01 vs. post-surgery; &P < 0.05, &&P < 0.01 vs. non-
surgery; ++P < 0.01, +++P < 0.001 vs. pre-surgery. Newman-Keuls test. BMI, Body mass index; WC, waist circumference; SPB, systolic; DBP, diastolic blood pressure;
ACEi, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; LDL-cholesterol, low-density lipoprotein; HDL, high-density lipoprotein-cholesterol;
T2DM, type 2 diabetes mellitus; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance index.
after BS (P < 0.05; Figure 4C). There was no correlation between
SIRT-1 expression and BMI (Figure 4D; r =−0.16, P = 0.225).
Bariatric Surgery Significantly
Reduces MMP-9 Activity and Lactate
Dehydrogenase Levels in Plasma
From Obese Patients
Gelatinase MMP-2 activity was similar in obese and non-obese
subjects, but significantly lower after BS (Figure 5A, P < 0.05
vs. obese). Gelatinase MMP-9 activity was significantly higher
in obese patients than in controls (Figure 5B; P < 0.01)
and normalized after BS (P < 0.001 vs. obese). Likewise,
specific measurement of the active MMP-9 form by ELISA
revealed a significant reduction in active MMP-9 levels after
BS (obese = 0.205 ± 0.01; Post-surgery = 0.153 ± 0.02;
P < 0.01), which positively correlated with BMI (Figure 5C;
r = 0.527, P < 0.001).
There was also a positive correlation between plasmatic MMP-
9 activity and protein carbonyls (r = 0.630, P < 0.001), and with
leukocyte and neutrophil number (r = 0.300 and P < 0.05 and
r = 0.298 and P < 0.05, respectively).
Lactate dehydrogenase (LDH) was significantly higher in
obese patients than in controls (P < 0.001) and significantly
diminished in the Post-surgery group (Figure 6A, P < 0.01 vs.
obese). A positive correlation was observed between LDH levels
and BMI (Figure 6B; r = 0.547, P < 0.001).
Mechanical studies performed in omental arteries from obese
patients evidenced a stiffness index β of 13.9 ± 2.5 (n = 11), as
an index of intrinsic arterial stiffness. In obese patients, we found
a significant correlation between LDH and the stiffness index β
(r = 0.829, P < 0.001).
DISCUSSION
The study demonstrates that both abnormal plasma MMP-9 and
PBMCs AMPK activities are reversed by BS. Interestingly, we
found a positive correlation between leukocyte and neutrophil
number and MMP-9 activity. Moreover, we describe for the
first time a relationship between plasmatic LDH levels and the
stiffness index β, as a marker of intrinsic arterial stiffness in
omental arteries from morbid obese patients, and a correlation
between AMPK and MMP-9 activity and LDH values. Finally, as
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FIGURE 2 | (A,B) Diagram bars shows protein carbonyls (A) and uric acid (UA) concentrations (B) in plasma samples from non-obese (white bar, n = 7), obese (gray
bar, n = 31) and post-surgery (black bar, n = 17) patients. (C) Correlation between protein carbonyl concentrations in plasma and BMI. (D) Correlation between
plasmatic UA levels and BMI. White triangles correspond to non-obese, white circles correspond to obese and black circles correspond to Post-surgery. Data are
expressed as mean ± SEM. #p < 0.05 and ###p < 0.001 compared with the non-obese group. ∗p < 0.05 and ∗∗∗p < 0.001 compared with the obese group.
BS has been shown to effectively normalize all these parameters,
we suggest that plasma MMP-9 and PBMCs AMPK activities
might potentially be used as markers of cardiovascular risk in
patients with morbid obesity.
Obesity is an established risk factor for several CVDs and it
may be associated with early vascular alterations. The presence of
classic CV risk factors (T2DM, hyperlipidemia and hypertension)
in obese subjects increases the risk of accelerating arterial
stiffness, especially if obesity appears at early ages (Wildman et al.,
TABLE 2 | Hemogram and CRP levels.
Non-obese Obese
Variable control Obese post-surgery
(N = 7) (N = 31) (N = 17)
No surgery Pre-surgery
(N = 14) (N = 17)
HEMOGRAM
Leukocytes (∗103 µl) 6.8 ± 0.3 7.8 ± 0.5 7.7 ± 0.5 5.7 ± 0.2∗∗∗
Neutrophils (∗103 µl) 4.1 ± 0.4 4.9 ± 0.3 4.6 ± 0.4 3.4 ± 0.2∗∗
Eosinophils (∗103 µl) 0.2 ± 0.09 0.22 ± 0.03 0.25 ± 0.05 0.16 ± 0.02
Monocytes (∗103 µl) 0.5 ± 0.03 0.52 ± 0.03 0.56 ± 0.05 0.42 ± 0.18∗∗
Lymphocytes (∗103 µl) 1.9 ± 0.1 2.2 ± 0.2 2.2 ± 0.1 1.7 ± 0.1∗∗
CRP (mg/dl) 0.16 ± 0.01 1.03 ± 0.2## 1.39 ± 0.31## 0.47 ± 0.09∗
Data are expressed as mean ± SEM. Data were compared using one-way ANOVA,
∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001 vs. obese, ##P < 0.01 vs. control. Newman–
Keuls test.
2003; Woo et al., 2004; Sato et al., 2005; Safar et al., 2006). In our
study, the mean age of obese subjects was 46 years and over 70%
of them already presented CV risk factors. Insulin resistance and
a low-grade inflammatory state are common physiopathological
mechanisms in obesity and T2DM. Therefore, we did not
detect differences in arterial stiffness-related parameters between
obese groups (non-surgery vs. pre-surgery). Moreover, 11 of
17 patients already exhibited an elevated intrinsic stiffness in
omental arteries, as shown by stiffness index β over 10.2, which
indicates pathological stiffness in this group (Sato et al., 2013)
and is a predictor of all-cause mortality (Willum-Hansen et al.,
2006; Mitchell et al., 2010; Vlachopoulos et al., 2010). Previous
studies also evidenced increased arterial stiffness in obese patients
(Dangardt et al., 2013; Pal and Radavelli-Bagatini, 2013; Arner
et al., 2015; Cote et al., 2015; Strasser et al., 2015; Manco
et al., 2017) assessed by the determination of either the PWV
or the augmentation index; parameters that are dependent on
blood pressure levels and markers of systemic but not intrinsic
arterial stiffness (Matsui et al., 2004). In addition, Savoia et al.
(2008), have described an increased stiffness index β in gluteal
subcutaneous arteries from hypertensive patients compared to
normotensive subjects, thus suggesting a relationship between an
increased stiffness and BP in hypertension. Moreover, a recent
study from our group performed in an animal model of diet-
induced obesity has also shown an association between the
stiffness index β in mesenteric resistance arteries and PWV
(Gil-Ortega et al., 2016). Nevertheless, a relationship between
intrinsic stiffness of omental arteries stated by the stiffness
index β and PWV has not been clearly stated yet. Nevertheless,
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FIGURE 3 | (A–E) Correlations between BMI and total leukocytes (A), lymphocytes (B), neutrophils (C), monocytes (D), and eosinophils (E). White triangles
correspond to non-obese, white circles correspond to obese and black circles correspond to Post-surgery.
FIGURE 4 | (A) Representative immunoblots of p-AMPK/AMPK and β-actin expression in PBMCs from non-obese, obese and post-surgery patients. Diagram bars
show the result of densitometric analysis of p-AMPK/AMPK immunoblots expressed as a percentage of p-AMPK/AMPK in the non-obese group. (B) Correlation
between p-AMPK/AMPK and BMI. (C) Representative immunoblots of SIRT1 and β-actin expression in PBMCs from non-obese, obese and post-surgery patients.
Diagram bars show the result of densitometric analysis of SIRT1/β-actin immunoblots expressed as a percentage of SIRT1/β-actin in the non-obese group.
(D) Correlation between SIRT1/β-actin and BMI. Data are expressed as mean ± SEM of ≥ 7 determinations per group. #p < 0.05 and ##p < 0.01 compared with
the non-obese group. ∗p < 0.05 and ∗∗∗p < 0.001 compared with the obese group.
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FIGURE 5 | (A) Representative cropped immunoblots of MMP-2 activity in plasma samples from non-obese, obese and Post-surgery patients. Diagram bars show
the result of densitometric analysis of MMP-2 activity expressed as a percentage of MMP-2 activity in the non-obese group. (B) Representative cropped
immunoblots of MMP-9 activity in plasma samples from non-obese, obese and Post-surgery patients. Diagram bars show the result of densitometric analysis of
MMP-9 activity expressed as a percentage of MMP-9 activity in the non-obese group. (C) Correlation between MMP-9 activity and BMI. White triangles correspond
to non-obese, white circles correspond to obese and black circles correspond to Post-surgery. Data are expressed as mean ± SEM of ≥ 7 determinations per
group. ##p < 0.01 compared with the non-obese group. ∗p < 0.05 and ∗∗∗p < 0.001 compared with the obese group.
FIGURE 6 | (A) Diagram bars shows LDH concentrations in plasma samples from non-obese, obese and Post-surgery patients. Data are expressed as
mean ± SEM of ≥7 determinations per group. ###p < 0.001 compared with the non-obese group. ∗∗p < 0.01 compared with the obese group. (B) Correlation
between LDH concentrations and BMI. White triangles correspond to non-obese, white circles correspond to obese and black circles correspond to Post-surgery.
though no direct comparison can be established with our results,
changes in intrinsic arterial stiffness precede changes in systemic
arterial stiffness (Sehgel et al., 2013). The early identification of
patients with altered intrinsic stiffness might thus be key for risk
assessment and the prevention of further CV damage.
Several pathophysiological mechanisms like chronic low-
grade inflammation and immune activation, oxidative stress,
and ECM remodeling are involved in the interaction between
obesity and arterial stiffness (Leopold, 2013; Aroor et al., 2018).
Moreover, a strong association has been described in women
between obesity and increased total lymphocyte counts and white
blood cells (Womack et al., 2007). Our obese patients had very
high CRP levels, but reached normal levels after BS. CRP directly
induces endothelial dysfunction through a reduction in nitric
oxide production (Venugopal et al., 2002) and favors oxidative
stress. This is in accordance with the oxidative protein damage
and increased UA levels observed in the obese group. UA is
considered a powerful scavenger of free radicals, which are
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increased in patients with obesity and insulin resistance, probably
as a compensatory mechanism to protect against oxidative
damage (Fabbrini et al., 2014). The fact that these parameters
reach normal values is in accordance with the beneficial effect of
BS on inflammatory and oxidative stress status (Kopp et al., 2005;
Sheu et al., 2008). Moreover, there is a reduction in lymphocytes,
leukocytes, neutrophils and monocytes in the hemogram of obese
patients after BS that correlates with BMI.
Inflammation may induce elastin degradation and changes
in the ECM composition through MMP (MMP-2 and MMP-9)
activation, thus resulting in an accumulation of stiffer, uncoiled
collagen (Galis and Khatri, 2002). Similarly to other studies, our
obese patients show a significant increase in MMP-9 activity
(Laimer et al., 2005; Derosa et al., 2008; Madsen et al., 2009) that
correlates with BMI. Under the influence of pro-inflammatory
cytokines, neutrophils induce MMP-9 activity and contribute
to microvascular complications (Galis and Khatri, 2002). In
this context, we observed a positive, significant relationship in
obese patients between neutrophil number and MMP-9 activity,
which suggests that neutrophil number may be highlighted as a
marker of ECM remodeling. Moreover, the positive correlation
between MMP-9 activity and circulating carbonyl levels in obese
patients is consistent with the traditional concept that MMP-9
expression is inducible through several mechanisms, the most
important of which is the action of reactive oxygen species (ROS)
(Kuhad et al., 2015). Pleiotropic effects of statins include the
reduction of MMP-9 activity and other inflammation markers
(Guerrero-Romero and Rodriguez-Moran, 2005). Therefore, an
effect of the treatment on these parameters in addition to BS
cannot be excluded.
One of the most interesting results of our study is the
increased LDH level in obese patients that is reduced after
BS and correlates with BMI. Nutritional diseases such as
obesity have been associated with changes in mitochondrial
oxidative phosphorylation and changes in the phenotype of
vascular smooth muscle cells (VSMCs) (Chiong et al., 2014).
The correlation between LDH and the stiffness index β might
suggest an association between LDH and arterial stiffness
associated with obesity.
Lymphocyte mitochondrial physiology seems to be associated
with nutritional status (Briet et al., 2003) and other cell type
metabolic alterations. Therefore, it might be considered an
interesting biomarker of metabolic status (Cortez et al., 2012). In
this context, we used PBMCs to determine both AMPK activity
and SIRT-1 expression in controls vs. obese vs. Post-surgery
patients. AMPK is a metabolic sensor. It reduces inflammation,
oxidative stress and vascular remodeling (Garcia-Prieto et al.,
2015a) and is dysregulated in obesity (Gauthier et al., 2011; Xu
et al., 2012). In accordance with these studies, we detected a
significant reduction in AMPK activity in obese patients that
was reversed by BS. Notably, AMPK activation also favors the
switch of the synthetic phenotype of VSMCs toward a contractile
phenotype (Stone et al., 2013). SIRT-1 can activate AMPK but
also has wide-ranging effects on metabolic homeostasis, mainly
as a regulator of mitochondrial integrity and by reducing inflam-
matory and oxidative stress tone (Kida and Goligorsky, 2016).
In our study, we found an increase in SIRT-1 expression after
BS. Moreover, since it has been suggested that SIRT-1 plays a key
role in CV protection, SIRT-1 overexpression could contribute to
reducing CV risk after BS.
Altogether, these data demonstrate that alterations in both
MMP-9 and AMPK activities might play a key role in the
development of arterial stiffness. In addition, other factors that
are altered in obesity like LDH, SIRT-1 expression, oxidative
stress markers or immune disorders could also contribute to
vascular damage.
CONCLUSION
A limitation of this study is that we did not measure intrinsic
arterial stiffness in omental arteries after BS for obvious
ethical reasons. Thus, we cannot conclude that modification in
abnormal AMPK, LDH, and MMP-9 activities has an impact
on intrinsic arterial stiffness in these patients. Further studies
are required to answer this question. Nonetheless, several
studies have demonstrated the relationship between weight loss
(i.e., after lifestyle modifications or surgical interventions) and
the reduction of arterial stiffness in both obese animal models
and morbid obese patients (Shargorodsky et al., 2006; Rider et al.,
2010; Weisbrod et al., 2013; Brunner et al., 2015; Hudson et al.,
2017; Manco et al., 2017; Backdahl et al., 2018). In conclusion,
since pAMPK, LDH and MMP-9 activities might be easily
measured in blood samples, they could be systematically used as
potential markers of CV risk and allow for the early identification
of patients with an altered intrinsic stiffness and the prevention
of further CV damage.
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